

H Clifford Lane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2159442/publications.pdf>

Version: 2024-02-01

215
papers

41,881
citations

10389
72
h-index

2448
197
g-index

220
all docs

220
docs citations

220
times ranked

54805
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). <i>Clinical Trials</i> , 2022, 19, 52-61.	1.6	16
2	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. <i>Lancet</i> , The, 2022, 399, 530-540.	13.7	48
3	Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 622-635.	9.1	135
4	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243.	3.9	56
5	RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19. <i>JCI Insight</i> , 2022, 7, .	5.0	17
6	Association of Lower Exposure Risk With Paucisymptomatic/Asymptomatic Infection, Less Severe Disease, and Unrecognized Ebola Virus Disease: A Seroepidemiological Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac052.	0.9	7
7	DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021Åupdate). <i>Nucleic Acids Research</i> , 2022, 50, W216-W221.	14.5	1,694
8	Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. <i>Aids</i> , 2022, Publish Ahead of Print, .	2.2	7
9	QuasiSeq: profiling viral quasispecies via self-tuning spectral clustering with PacBio long sequencing reads. <i>Bioinformatics</i> , 2022, 38, 3192-3199.	4.1	3
10	A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings. <i>Annals of Internal Medicine</i> , 2022, 175, 969-979.	3.9	99
11	Research in the Context of a Pandemic. <i>New England Journal of Medicine</i> , 2021, 384, 755-757.	27.0	50
12	Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. <i>Annals of Internal Medicine</i> , 2021, 174, 93-95.	3.9	38
13	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. <i>New England Journal of Medicine</i> , 2021, 384, 619-629.	27.0	741
14	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 905-914.	27.0	357
15	Characterization of Ebola Virusâ€Associated Eye Disease. <i>JAMA Network Open</i> , 2021, 4, e2032216.	5.9	12
16	Genome-wide association study of high-sensitivity C-reactive protein, D-dimer, and interleukin-6 levels in multiethnic HIV+ cohorts. <i>Aids</i> , 2021, 35, 193-204.	2.2	6
17	PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. <i>Clinical Infectious Diseases</i> , 2021, 73, 1849-1856.	5.8	24
18	2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1898-1906.	3.0	1

#	ARTICLE	IF	CITATIONS
19	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. <i>Journal of Infectious Diseases</i> , 2021, 224, 2053-2063.	4.0	6
20	SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. <i>Annals of Internal Medicine</i> , 2021, 174, 687-690.	3.9	64
21	Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1151-1158.	3.9	16
22	Prevalence of HIV Infection and Resistance Mutations in Patients Hospitalized for Febrile Illness in Indonesia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 960-965.	1.4	3
23	The impact of the 2014 Ebola epidemic on HIV disease burden and outcomes in Liberia West Africa. <i>PLoS ONE</i> , 2021, 16, e0257049.	2.5	0
24	Natural Occurring Polymorphisms in HIV-1 Integrase and RNase H Regulate Viral Release and Autoprocessing. <i>Journal of Virology</i> , 2021, 95, e0132321.	3.4	7
25	Tackling the burden of mumps in the military: A report of the Defense Health Board. <i>Vaccine</i> , 2021, 39, 6186-6188.	3.8	0
26	Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. <i>Trials</i> , 2021, 22, 86.	1.6	9
27	Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa613.	0.9	6
28	The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. <i>Aids</i> , 2021, 35, 783-789.	2.2	2
29	Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3+PD1 ^{hi} /low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques. <i>Journal of Infectious Diseases</i> , 2020, 221, 523-533.	4.0	5
30	Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 2317-2324.	5.8	10
31	Four Decades of HIV/AIDS “ Much Accomplished, Much to Do. <i>New England Journal of Medicine</i> , 2020, 383, 1-4.	27.0	106
32	Defective HIV-1 proviruses produce viral proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3704-3710.	7.1	150
33	Covid-19 “ Navigating the Uncharted. <i>New England Journal of Medicine</i> , 2020, 382, 1268-1269.	27.0	1,393
34	An observational prospective cohort study of the epidemiology of hospitalized patients with acute febrile illness in Indonesia. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007927.	3.0	20
35	Remdesivir for the Treatment of Covid-19 “ Final Report. <i>New England Journal of Medicine</i> , 2020, 383, 1813-1826.	27.0	5,834
36	Adult and paediatric haematology and clinical chemistry laboratory reference limits for Liberia. <i>African Journal of Laboratory Medicine</i> , 2020, 9, 1080.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 941-950.	10.7	83
38	Evaluation of an antibody to $\hat{1} \pm \langle \text{sub} \rangle 4 \langle / \text{sub} \rangle \hat{1}^2 \langle \text{sub} \rangle 7 \langle / \text{sub} \rangle$ in the control of SIVmac239- <i>nef-stop</i> infection. <i>Science</i> , 2019, 365, 1025-1029.	12.6	29
39	An open-label phase 1 clinical trial of the anti- $\hat{1} \pm \langle \text{sub} \rangle 4 \langle / \text{sub} \rangle \hat{1}^2 \langle \text{sub} \rangle 7 \langle / \text{sub} \rangle$ monoclonal antibody vedolizumab in HIV-infected individuals. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	40
40	Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 951-963.	10.7	99
41	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-“Naive” Participants From the Strategic Timing of AntiRetroviral Treatment Trial. <i>Journal of Infectious Diseases</i> , 2019, 220, 1325-1334.	4.0	18
42	A Longitudinal Study of Ebola Sequelae in Liberia. <i>New England Journal of Medicine</i> , 2019, 380, 924-934.	27.0	104
43	A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. <i>New England Journal of Medicine</i> , 2019, 381, 2293-2303.	27.0	1,171
44	A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	21
45	Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 207-215.	2.1	1
46	PREVAIL I Cluster Vaccination Study With rVSV $\hat{1}^2$ “G-ZEBOV-GP as Part of a Public Health Response in Liberia. <i>Journal of Infectious Diseases</i> , 2019, 219, 1634-1641.	4.0	12
47	Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller. <i>JCI Insight</i> , 2019, 4, .	5.0	6
48	Brain 18F-FDG PET of SIV-infected macaques after treatment interruption or initiation. <i>Journal of Neuroinflammation</i> , 2018, 15, 207.	7.2	9
49	2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2186-2196.	3.0	4
50	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 330-341.	27.0	314
51	Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47phox. <i>Scientific Reports</i> , 2017, 7, 43441.	3.3	20
52	Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 500-511.	10.7	85
53	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. <i>New England Journal of Medicine</i> , 2017, 377, 1438-1447.	27.0	199
54	Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. <i>Lancet Infectious Diseases</i> , 2017, 17, 1255-1265.	9.1	70

#	ARTICLE	IF	CITATIONS
55	STING is an essential mediator of the Ku70-mediated production of IFN- γ 1 in response to exogenous DNA. Science Signaling, 2017, 10, .	3.6	100
56	Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. Open Forum Infectious Diseases, 2017, 4, ofx262.	0.9	65
57	CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies. PLoS ONE, 2017, 12, e0187912.	2.5	2
58	IL-7-dependent STAT1 activation limits homeostatic CD4+ T cell expansion. JCI Insight, 2017, 2, .	5.0	15
59	Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation. PLoS ONE, 2016, 11, e0167091.	2.5	38
60	A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. New England Journal of Medicine, 2016, 375, 1448-1456.	27.0	429
61	Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8783-8788.	7.1	282
62	Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients. Aids, 2016, 30, 2487-2493.	2.2	26
63	INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study. Journal of Infectious Diseases, 2016, 213, 574-578.	4.0	22
64	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. Journal of Antimicrobial Chemotherapy, 2016, 71, 2928-2937.	3.0	7
65	Conducting clinical trials in outbreak settings: Points to consider. Clinical Trials, 2016, 13, 92-95.	1.6	35
66	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. Clinical Trials, 2016, 13, 49-56.	1.6	63
67	Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa. Southern African Journal of HIV Medicine, 2016, 17, 450.	0.9	4
68	Activated platelet-T-cell conjugates in peripheral blood of patients with HIV infection. Aids, 2015, 29, 1297-1308.	2.2	45
69	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. New England Journal of Medicine, 2015, 373, 795-807.	27.0	2,232
70	Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer. Journal of Clinical Oncology, 2015, 33, 74-82.	1.6	571
71	HIV-1 Treated Patients with Undetectable Viral Loads have Lower Levels of Innate Immune Responses via Cytosolic DNA Sensing Systems Compared with Healthy Uninfected Controls. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	5
72	Chronic Exposure to Type-I IFN under Lymphopenic Conditions Alters CD4 T Cell Homeostasis. PLoS Pathogens, 2014, 10, e1003976.	4.7	24

#	ARTICLE	IF	CITATIONS
73	A Model of Federal Interagency Cooperation: The National Interagency Confederation for Biological Research. <i>Biosecurity and Bioterrorism</i> , 2014, 12, 144-150.	1.2	5
74	Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus. <i>Aids</i> , 2014, 28, 1091-1099.	2.2	56
75	siRNA enhances DNA-mediated interferon lambda-1 response through crosstalk between RIG-I and IFI16 signalling pathway. <i>Nucleic Acids Research</i> , 2014, 42, 583-598.	14.5	30
76	An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1104-1110.	3.0	13
77	Plasma Interleukin-27 (IL-27) Levels Are Not Modulated in Patients with Chronic HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e98989.	2.5	14
78	Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies. <i>PLoS ONE</i> , 2014, 9, e101785.	2.5	31
79	Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 571-577.	7.2	28
80	Interleukin-27 treated human macrophages induce the expression of novel microRNAs which may mediate anti-viral properties. <i>Biochemical and Biophysical Research Communications</i> , 2013, 434, 228-234.	2.1	43
81	Enhanced Effector Function of CD8+ T Cells From Healthy Controls and HIV-Infected Patients Occurs Through Thrombin Activation of Protease-Activated Receptor 1. <i>Journal of Infectious Diseases</i> , 2013, 207, 638-650.	4.0	38
82	IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. <i>Journal of Experimental Medicine</i> , 2013, 210, 517-534.	8.5	66
83	Interleukin-2 Inhibits HIV-1 Replication in Some Human T Cell Lymphotropic Virus-1-infected Cell Lines via the Induction and Incorporation of APOBEC3G into the Virion. <i>Journal of Biological Chemistry</i> , 2013, 288, 17812-17822.	3.4	13
84	Cerebrospinal Fluid HIV-1 Compartmentalization in a Patient With AIDS and Acute Varicella-Zoster Virus Meningomyelradiculitis. <i>Clinical Infectious Diseases</i> , 2013, 57, e135-e142.	5.8	18
85	Elevations in D-dimer and C-reactive protein are associated with the development of osteonecrosis of the hip in HIV-infected adults. <i>Aids</i> , 2013, 27, 591-595.	2.2	17
86	HIV immune activation drives increased Eomes expression in memory CD8 T cells in association with transcriptional downregulation of CD127. <i>Aids</i> , 2013, 27, 1867-1877.	2.2	18
87	The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies. <i>PLoS ONE</i> , 2013, 8, e57121.	2.5	54
88	Regulatory T Cells in HIV-1 Infection: The Good, the Bad, and the Ugly. <i>Journal of Infectious Diseases</i> , 2012, 205, 1479-1482.	4.0	21
89	DAVID-WS: a stateful web service to facilitate gene/protein list analysis. <i>Bioinformatics</i> , 2012, 28, 1805-1806.	4.1	955
90	The CD8 ⁺ HLA-DR ⁺ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls. <i>European Journal of Immunology</i> , 2012, 42, 2608-2620.	2.9	30

#	ARTICLE	IF	CITATIONS
91	The role of cytokines in the pathogenesis and treatment of HIV infection. Cytokine and Growth Factor Reviews, 2012, 23, 207-214.	7.2	68
92	Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. PLoS ONE, 2012, 7, e44454.	2.5	456
93	Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease. PLoS ONE, 2012, 7, e24243.	2.5	89
94	Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 36-43.	2.1	142
95	IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. Blood, 2011, 118, 6845-6848.	1.4	84
96	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood, 2011, 117, 4787-4795.	1.4	165
97	Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. Blood, 2011, 118, 262-270.	1.4	40
98	Cutting Edge: Ku70 Is a Novel Cytosolic DNA Sensor That Induces Type III Rather Than Type I IFN. Journal of Immunology, 2011, 186, 4541-4545.	0.8	211
99	Clinical Evaluation of the Potential Utility of Computational Modeling as an HIV Treatment Selection Tool by Physicians with Considerable HIV Experience. AIDS Patient Care and STDs, 2011, 25, 29-36.	2.5	20
100	Biomarkers in HIV disease. Current Opinion in HIV and AIDS, 2010, 5, 459-462.	3.8	9
101	Interferon- γ Produces Significant Decreases in HIV Load. Journal of Interferon and Cytokine Research, 2010, 30, 461-464.	1.2	37
102	Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2010, 18, 2-6.	2.9	30
103	Identification and Characterization of CRF02_AG, CRF06_cpx, and CRF09_cpx Recombinant Subtypes in Mali, West Africa. AIDS Research and Human Retroviruses, 2009, 25, 45-55.	1.1	9
104	IL-15 acts as a potent inducer of CD4 ⁺ CD25 ^{hi} cells expressing FOXP3. European Journal of Immunology, 2008, 38, 1621-1630.	2.9	64
105	Effects of Delays in Peripheral Blood Processing, Including Cryopreservation, on Detection of CD31 Expression on Naïve CD4 T Cells. Vaccine Journal, 2008, 15, 1141-1143.	3.1	1
106	IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. Aids, 2008, 22, 39-45.	2.2	86
107	HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19851-19856.	7.1	111
108	CD4 T Cell Survival after Intermittent Interleukin-2 Therapy Is Predictive of an Increase in the CD4 T Cell Count of HIV-Infected Patients. Journal of Infectious Diseases, 2008, 198, 843-850.	4.0	18

#	ARTICLE	IF	CITATIONS
109	Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood, 2008, 112, 287-294.	1.4	243
110	Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. PLoS Medicine, 2008, 5, e203.	8.4	1,398
111	Infections in the immunocompromised host. , 2008, , 477-491.		0
112	DAVID gene ID conversion tool. Bioinformatics, 2008, 2, 428-430.	0.5	156
113	DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Research, 2007, 35, W169-W175.	14.5	1,934
114	Loss of Naïve Cells Accompanies Memory CD4 + T-Cell Depletion during Long-Term Progression to AIDS in Simian Immunodeficiency Virus-Infected Macaques. Journal of Virology, 2007, 81, 893-902.	3.4	50
115	CD4+T Cell Responses to Interleukin-2 Administration in HIV-Infected Patients Are Directly Related to the Baseline Level of Immune Activation. Journal of Infectious Diseases, 2007, 196, 677-683.	4.0	15
116	Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood, 2007, 109, 1841-1849.	1.4	94
117	Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood, 2007, 110, 501-508.	1.4	51
118	DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics, 2007, 8, 426.	2.6	510
119	Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients. Aids, 2006, 20, 361-369.	2.2	13
120	Decreased CD127 Expression on T Cells in HIV-1-infected Adults Receiving Antiretroviral Therapy With or Without Intermittent IL-2 Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 537-544.	2.1	24
121	A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK "Vanguard Study. PLOS Clinical Trials, 2006, 1, e3.	3.5	19
122	Explaining, Predicting, and Treating HIV-Associated CD4 Cell Loss. JAMA - Journal of the American Medical Association, 2006, 296, 1523.	7.4	18
123	Functional Correlation between a Novel Amino Acid Insertion at Codon 19 in the Protease of Human Immunodeficiency Virus Type 1 and Polymorphism in the p1/p6 Gag Cleavage Site in Drug Resistance and Replication Fitness. Journal of Virology, 2006, 80, 6136-6145.	3.4	26
124	A Transcription Inhibitor, Actinomycin D, Enhances HIV-1 Replication Through an Interleukin-6-Dependent Pathway. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 388-397.	2.1	9
125	Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected Individuals. Human Gene Therapy, 2005, 16, 1065-1074.	2.7	69
126	Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. Journal of Clinical Investigation, 2005, 115, 2139-2148.	8.2	115

#	ARTICLE	IF	CITATIONS
127	In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients. <i>Journal of Clinical Investigation</i> , 2005, 115, 1839-1847.	8.2	109
128	Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected Individuals. <i>Human Gene Therapy</i> , 2005, .	2.7	0
129	CD4 Cell Response to 3 Doses of Subcutaneous Interleukin 2: Meta-analysis of 3 Vanguard Studies. <i>Clinical Infectious Diseases</i> , 2004, 39, 115-122.	5.8	109
130	Immune-based Therapies for HIV Infection. , 2004, , 931-945.		0
131	BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases in CD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro. <i>Clinical Immunology</i> , 2004, 113, 248-255.	3.2	10
132	Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. <i>Blood</i> , 2004, 103, 3282-3286.	1.4	47
133	IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. <i>Blood</i> , 2004, 104, 775-780.	1.4	93
134	A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human Interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ t cells. <i>Clinical Immunology</i> , 2003, 106, 188-196.	3.2	21
135	DAVID: Database for Annotation, Visualization, and Integrated Discovery. <i>Genome Biology</i> , 2003, 4, 1.	8.8	1,411
136	A Randomized, Double-Blinded, Placebo-Controlled Trial of Intermittent Administration of Interleukin-2 and Prednisone in Subjects Infected with Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2003, 188, 531-536.	4.0	13
137	Macrophage-Tropic Simian/Human Immunodeficiency Virus Chimeras Use CXCR4, Not CCR5, for Infections of Rhesus Macaque Peripheral Blood Mononuclear Cells and Alveolar Macrophages. <i>Journal of Virology</i> , 2003, 77, 13042-13052.	3.4	37
138	Actinomycin D Induces High-Level Resistance to Thymidine Analogs in Replication of Human Immunodeficiency Virus Type 1 by Interfering with Host Cell Thymidine Kinase Expression. <i>Journal of Virology</i> , 2003, 77, 1011-1020.	3.4	20
139	Cutting Edge: L-Selectin (CD62L) Expression Distinguishes Small Resting Memory CD4+ T Cells That Preferentially Respond to Recall Antigen. <i>Journal of Immunology</i> , 2003, 170, 28-32.	0.8	101
140	Incomplete CD4 T Cell Recovery in HIV-1 Infection After 12 Months of Highly Active Antiretroviral Therapy Is Associated With Ongoing Increased CD4 T Cell Activation and Turnover. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 125-133.	2.1	110
141	Increases in CD4+ T Lymphocytes Occur Without Increases in Thymic Size in HIV-Infected Subjects Receiving Interleukin-2 Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 299-303.	2.1	10
142	DAVID: Database for Annotation, Visualization, and Integrated Discovery. <i>Genome Biology</i> , 2003, 4, P3.	8.8	4,682
143	Increasing CD4+T Cells Specific for Tuberculosis Correlate with Improved Clinical Immunity after Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 969-975.	1.1	20
144	Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10712-10717.	7.1	65

#	ARTICLE	IF	CITATIONS
145	Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13813-13818.	7.1	22
146	Randomized, Open-Label Study of the Impact of Two Doses of Subcutaneous Recombinant Interleukin-2 on Viral Burden in Patients With HIV-1 Infection and CD4+ Cell Counts of $\geq 300/\text{mm}^3$: CPCRA 059. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 221-231.	2.1	32
147	Randomized, Open-Label Study of the Impact of Two Doses of Subcutaneous Recombinant Interleukin-2 on Viral Burden in Patients With HIV-1 Infection and CD4+ Cell Counts of $\geq 300/\text{mm}^3$: CPCRA 059. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 221-231.	2.1	34
148	High Prevalence of Osteonecrosis of the Femoral Head in HIV-Infected Adults. Annals of Internal Medicine, 2002, 137, 17.	3.9	153
149	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/CD25+ T cells. Blood, 2002, 100, 2159-2167.	1.4	69
150	The Evaluation of Subcutaneous Proleukin® (interleukin-2) in a Randomized International Trial. Contemporary Clinical Trials, 2002, 23, 198-220.	1.9	81
151	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4+/CD25+ T cells. Blood, 2002, 100, 2159-2167.	1.4	2
152	Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood, 2002, 100, 2159-67.	1.4	19
153	Cytokine-based therapies for HIV infection. Aids, 2001, 15, S183-S191.	2.2	5
154	CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. Aids, 2001, 15, 1765-1775.	2.2	50
155	Bioterrorism: A clear and present danger. Nature Medicine, 2001, 7, 1271-1273.	30.7	157
156	Amino Acid Deletion at Codon 67 and Thr-to-Gly Change at Codon 69 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Novel Drug Resistance Profiles. Journal of Virology, 2001, 75, 3988-3992.	3.4	32
157	Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV. Journal of Experimental Medicine, 2001, 194, 1731-1741.	8.5	203
158	A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. Aids, 2000, 14, 2509-2513.	2.2	33
159	Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2000, 284, 183.	7.4	158
160	High-Level Resistance to 3'-Azido-2-Deoxythymidine due to a Deletion in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1. Journal of Virology, 2000, 74, 1023-1028.	3.4	38
161	Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression. Aids, 2000, 14, 1709-1715.	2.2	38
162	Effects of Intermittent Interleukin-2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasi-Species Expression. Journal of Infectious Diseases, 2000, 182, 1063-1069.	4.0	31

#	ARTICLE	IF	CITATIONS
163	Longitudinal Changes in CD4+T Cell Antigen Receptor Diversity and Naive/Memory Cell Phenotype during 9 to 26 Months of Antiretroviral Therapy of HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1877-1886.	1.1	23
164	Relative Replication Fitness of a High-Level 3'-Azido-3'-Deoxythymidine-Resistant Variant of Human Immunodeficiency Virus Type 1 Possessing an Amino Acid Deletion at Codon 67 and a Novel Substitution (Thr→Gly) at Codon 69. <i>Journal of Virology</i> , 2000, 74, 10958-10964.	3.4	80
165	A Randomized Trial of High-versus Low-Dose Subcutaneous Interleukin-2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 1999, 179, 849-858.	4.0	149
166	Re-emergence of HIV after stopping therapy. <i>Nature</i> , 1999, 401, 874-875.	27.8	390
167	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. <i>Nature Medicine</i> , 1999, 5, 651-655.	30.7	400
168	Atovaquone Suspension in HIV-Infected Volunteers: Pharmacokinetics, Pharmacodynamics, and TMP-SMX Interaction Study. <i>Pharmacotherapy</i> , 1999, 19, 1050-1056.	2.6	41
169	HIV-1 replication in patients with undetectable plasma virus receiving HAART. <i>Lancet</i> , The, 1999, 353, 119-120.	13.7	142
170	Comparison of the Quantiplex Version 3.0 Assay and a Sensitized Amplicor Monitor Assay for Measurement of Human Immunodeficiency Virus Type 1 RNA Levels in Plasma Samples. <i>Journal of Clinical Microbiology</i> , 1999, 37, 3612-3614.	3.9	37
171	Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. <i>Nature Medicine</i> , 1998, 4, 852-856.	30.7	115
172	Human immunodeficiency virus disease: Changing patterns of intraocular inflammation. <i>American Journal of Ophthalmology</i> , 1998, 125, 374-382.	3.3	62
173	Telomere Length, Telomerase Activity, and Replicative Potential in HIV Infection: Analysis of CD4+ and CD8+T Cells from HIV-discordant Monozygotic Twins. <i>Journal of Experimental Medicine</i> , 1997, 185, 1381-1386.	8.5	126
174	Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. <i>Immunological Reviews</i> , 1997, 160, 43-54.	6.0	187
175	HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. <i>Nature Medicine</i> , 1997, 3, 533-540.	30.7	501
176	HIV antivirals and immune recovery. <i>Nature Medicine</i> , 1997, 3, 704-704.	30.7	0
177	Immune reconstitution in HIV infection. <i>Current Opinion in Immunology</i> , 1997, 9, 568-572.	5.5	39
178	Immune-based therapies in HIV infection. <i>Aids</i> , 1996, 10, S159-164.	2.2	16
179	Inhibition of Immunoreactive Tumor Necrosis Factor- α by a Chimeric Antibody in Patients Infected with Human Immunodeficiency Virus Type 1. <i>Journal of Infectious Diseases</i> , 1996, 174, 63-68.	4.0	71
180	Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus. <i>New England Journal of Medicine</i> , 1996, 335, 1350-1356.	27.0	429

#	ARTICLE	IF	CITATIONS
181	Biologic Response Modifiers (Interleukins and Interferons). , 1996, , 493-511.		2
182	Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nature Medicine, 1995, 1, 330-336.	30.7	372
183	Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection â€” A Preliminary Study. New England Journal of Medicine, 1995, 332, 567-575.	27.0	433
184	A unique syndrome of immunodeficiency and autoimmunity associated with absent T cell CD2 expression. Journal of Clinical Immunology, 1994, 14, 359-367.	3.8	8
185	A Phase I Study of Interferon-Î±2b in Combination with Interleukin-2 in Patients with Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 1994, 169, 981-989.	4.0	33
186	Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay. Journal of Clinical Immunology, 1993, 13, 185-192.	3.8	16
187	Immunologic Approaches to the Therapy of HIV-1 Infection. Annals of the New York Academy of Sciences, 1993, 685, 687-696.	3.8	5
188	A Study of the Safety and Survival of the Adoptive Transfer of Genetically Marked Syngeneic Lymphocytes in HIV-infected Identical Twins. Human Gene Therapy, 1993, 4, 659-680.	2.7	29
189	Indeterminate western blot patterns in a cohort of individuals at high risk for human immunodeficiency virus (HIV-1) exposure. Journal of Clinical Immunology, 1992, 12, 185-192.	3.8	16
190	Immunologic Abnormalities in HIV Infection. Hematology/Oncology Clinics of North America, 1991, 5, 215-228.	2.2	19
191	A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1991, 325, 1534-1538.	27.0	82
192	Effect of Aerosolized Pentamidine Prophylaxis on the Diagnosis of <i>Pneumocystis carinii</i> Pneumonia by Induced Sputum Examination in Patients Infected with the Human Immunodeficiency Virus. The American Review of Respiratory Disease, 1991, 144, 760-764.	2.9	69
193	Syngeneic Bone Marrow Transplantation and Adoptive Transfer of Peripheral Blood Lymphocytes Combined with Zidovudine in Human Immunodeficiency Virus (HIV) Infection. Annals of Internal Medicine, 1990, 113, 512.	3.9	65
194	Laboratory Methods in the Diagnosis and Prognostic Staging of infection with Human Immunodeficiency Virus Type 1. Clinical Infectious Diseases, 1990, 12, 912-930.	5.8	39
195	The immunology of HIV infection. Journal of the American Academy of Dermatology, 1990, 22, 1202-1205.	1.2	8
196	Effects of interferon-Î± in patients with aids-associated Kaposi's sarcoma are related to blood interferon levels and dose. Cytokine, 1990, 2, 247-252.	3.2	16
197	Acquired Immunodeficiency Syndrome. Dermatologic Clinics, 1990, 8, 771-786.	1.7	5
198	Interferon-Î± in Patients with Asymptomatic Human Immunodeficiency Virus (HIV) Infection. Annals of Internal Medicine, 1990, 112, 805.	3.9	212

#	ARTICLE	IF	CITATIONS
199	A phase I trial of recombinant human interferon- β in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). Journal of Clinical Immunology, 1989, 9, 351-361.	3.8	37
200	Zidovudine in Patients with Human Immunodeficiency Virus (HIV) Infection and Kaposi Sarcoma. Annals of Internal Medicine, 1989, 111, 41.	3.9	85
201	Host defense against Mycobacterium-avium complex. Journal of Clinical Immunology, 1988, 8, 234-243.	3.8	58
202	ANTI-RETROVIRAL EFFECTS OF INTERFERON- β IN AIDS-ASSOCIATED KAPOSI'S SARCOMA. Lancet, The, 1988, 332, 1218-1222.	13.7	246
203	Diagnosis of <i>Pneumocystis carinii</i> Pneumonia: Improved Detection in Sputum with Use of Monoclonal Antibodies. New England Journal of Medicine, 1988, 318, 589-593.	27.0	352
204	Trimetrexate for the Treatment of <i>Pneumocystis carinii</i> Pneumonia in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1987, 317, 978-985.	27.0	243
205	Combination chemotherapy of disseminated kaposi's sarcoma in patients with the acquired immune deficiency syndrome. American Journal of Medicine, 1987, 82, 456-462.	1.5	65
206	Peripheral t cell lymphoma presenting as hypereosinophilia with vasculitis. Clinical, pathologic, and immunologic features. American Journal of Medicine, 1987, 82, 539-545.	1.5	72
207	Clinical Pharmacokinetics of Suramin in Patients With HTLV-III/LAV Infection. Journal of Clinical Pharmacology, 1986, 26, 22-26.	2.0	130
208	Immunologic Reconstitution in the Acquired Immunodeficiency Syndrome. Annals of Internal Medicine, 1985, 103, 714.	3.9	42
209	Qualitative Analysis of Immune Function in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1985, 313, 79-84.	27.0	760
210	EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO. Lancet, The, 1985, 326, 627-630.	13.7	190
211	Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. American Journal of Medicine, 1985, 78, 417-422.	1.5	180
212	Ophthalmic Involvement in Acquired Immunodeficiency Syndrome. Ophthalmology, 1984, 91, 1092-1099.	5.2	321
213	Kaposi's Sarcoma of the Head and Neck in the Acquired Immune Deficiency Syndrome. Otolaryngology - Head and Neck Surgery, 1984, 92, 255-260.	1.9	30
214	Partial Immune Reconstitution in a Patient with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1984, 311, 1099-1103.	27.0	67
215	Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1983, 309, 453-458.	27.0	1,653